Key Points Even if it’s not being officially reported yet, its drug Casgevy is accruing revenue that will show up in earnest beginning next year. That being said, CRISPR Therapeutics’ developmental pipeline shows promise well beyond Casgevy’s potential. Largely lost in the noise is the fact that the company’s patented gene-editing know-how is an asset that can be monetized in many other ways. 10 stocks we like better than CRISPR Therapeutics › It's been a disappointing couple of years for shareholders of biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP) . This stock's barely up since the end of 2022, lagging the broad market's gains. It's not the performance that investors keeping tabs on this company were expecting, given its potential.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.